Cyclacel Pharmaceuticals Company Profile (NASDAQ:CYCC)

Analyst Ratings

Consensus Ratings for Cyclacel Pharmaceuticals (NASDAQ:CYCC) (?)
Ratings Breakdown: 1 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $60.00 (1,132.03% upside)

Analysts' Ratings History for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Show:
DateFirmActionRatingPrice TargetActions
10/16/2015HC WainwrightInitiated CoverageBuy$60.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/17/2014JMP SecuritiesDowngradeOutperform -> Market Perform$108.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/9/2016        
5/11/2016Q116($0.09)$512.00 million$139.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/24/2016Q4($0.08)($0.10)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.09)($0.08)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2015Q215($0.10)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015Q115($0.25)($0.19)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/24/2015Q414($0.26)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2014Q314($0.26)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014Q214($0.30)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q114($0.26)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/25/2014Q413($0.33)($0.19)$0.09 million$0.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q3($0.31)($0.31)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2013Q2 2013($0.10)$0.03 million$0.26 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2013Q1 2013($1.18)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2012Q312($0.37)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Current Dividend Information for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Annual Dividend:$0.15
Dividend Yield:3.08%
Payout Ratio:-2.66% (Based on Trailing 12 Months of Earnings)

Dividend History for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable DateShare
6/9/2016Annual$0.157/13/20167/17/20168/1/2016Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
11/20/2014Sam L BarkerDirectorBuy3,100$3.00$9,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2013Lloyd SemsDirectorBuy33,333$3.00$99,999.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2013Paul McbarronCFOBuy12,948$3.03$39,232.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2013Spiro George RombotisInsiderBuy100,000$3.00$300,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
DateHeadline
07/23/16 03:27 PMIs $60.024 Price Target Attainable For Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC)? - Investor Newswire
07/17/16 08:06 AMStrong Sell Calls For Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) At 0 - Investor Newswire
07/14/16 03:44 PMCyclacel Pharmaceuticals Inc (NASDAQ:CYCC) Shifting Institutional Investors Sentiment - Press Telegraph
07/14/16 06:16 AMCyclacel Pharmaceuticals Incorporated (NASDAQ:CYCC) Sellers Increased By 176.26% Their Shorts - Consumer Eagle
07/11/16 08:20 AMIs $60.024 Within Reach For Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC)? - Investor Newswire
07/06/16 09:21 PMBroker Outlook For Cyclacel Pharmaceuticals, Inc. (CYCC) - Fiscal Standard
07/06/16 04:02 PMCYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers -
07/04/16 03:18 PMCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Expected to Reach Highs Of $60.024 - Investor Newswire
07/04/16 03:18 PMBroker Outlook For The Week Ahead Cyclacel Pharmaceuticals, Inc. (CYCC) - Fiscal Standard
07/01/16 09:31 AMBrokers Issue Average Price Target Of 7.00 On Cyclacel Pharmaceuticals, Inc. (CYCC) - Fiscal Standard
06/30/16 09:04 AMCyclacel Pharmaceuticals Incorporated (NASDAQ:CYCC) Shorted Shares Increased By 176.26% - Press Telegraph
06/28/16 03:30 PMCyclacel Pharmaceuticals, Inc. (CYCC) Broker Price Targets For The Coming Week - Fiscal Standard
06/26/16 08:36 AMStrong Sell Calls Recommendations For Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) At 0 - Investor Newswire
06/24/16 10:16 AMCyclacel Pharma (CYCC) Enters $4M At Market Issuance Sales Agreement
06/23/16 08:30 PMNew Broker Ratings For Cyclacel Pharmaceuticals, Inc. (CYCC) - FTSE News
06/23/16 08:30 PMCyclacel Pharma (CYCC) Enters $4M At Market Issuance Sales Agreement - StreetInsider.com
06/23/16 03:39 PMCYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Mater -
06/22/16 03:42 PMCyclacel Pharmaceuticals, Inc. (CYCC) Current Analyst Ratings - Fiscal Standard
06/19/16 07:59 AMStrong Buy Calls Count For Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) At 1 - Investor Newswire
06/17/16 03:24 PMEndocyte, Inc. (NASDAQ:ECYT) increased 1.10%: Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), Freeport ... - KC Register
06/16/16 03:32 PMCyclacel Pharma (CYCC) Regains Nasdaq Listing Compliance - StreetInsider.com
06/08/16 10:29 AMStocks inside Analysts Spotlight: Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) , Skyline Medical Inc. (NASDAQ ... - Street Updates
06/07/16 03:36 PMAnalyst Overview: Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) - News Oracle
06/07/16 03:36 PMCyclacel Pharmaceuticals (NASDAQ:CYCC) & Kite Pharma Inc (NASDAQ:KITE) Healthcare Stocks on the Run - Wall Street 24
06/07/16 11:22 AMActive Stocks in Pre-Market: Cyclacel Pharmaceuticals Inc(NASDAQ:CYCC), Amazon.com, Inc.(NASDAQ:AMZN) - iStreetWire
06/06/16 03:21 PMCyclacel Pharmaceuticals, (NASDAQ:CYCC) Went Down -3.89%: Cynapsus Therapeutics (NASDAQ:CYNA), Twenty ... - KC Register
06/06/16 03:21 PMCyclacel Pharmaceuticals Inc (CYCC) Stock Shoots up on Phase 1 DNA Damage Response Program Data - Bidness ETC
06/06/16 03:13 PMCyclacel Pharma (CYCC) Stock Skyrockets 50% on Positive Phase 1 Data -
06/03/16 12:04 PMCYCLACEL PHARMACEUTICALS, INC. Financials -
06/01/16 09:42 PMBroker Watchlist: Cyclacel Pharmaceuticals, Inc. (CYCC) - Share Trading News - Broker Watchlist: Cyclacel Pharmaceuticals, Inc. (CYCC)Share Trading NewsThey now have a USD 9 price target on the stock. The share price of Cyclacel Pharmaceuticals, Inc. (CYCC) was unchanged +0.00% during the last trading session, with a day high of 0.00. 0 shares were traded on Cyclacel Pharmaceuticals, Inc.'s last ...
06/01/16 12:32 PMCyclacel Pharmaceuticals, Inc. :CYCC-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 -
05/31/16 03:36 PMStrong Sell Calls Count For Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) At 0 - Investor Newswire - Strong Sell Calls Count For Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) At 0Investor NewswireCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) has a total of 1 Strong Buy calls and 0 Strong Sell advises as of 2016-05-30. Zacks uses a rating procedure which assigns scores to stocks on a narrow 1-5 scale. When a stock gets a score of 1 or 2, it is ...and more »
05/31/16 06:03 AMSplits Calendar: Cyclacel Pharma splits before market open today (1:12 ratio) -
05/27/16 04:07 PMCyclacel Announces Reverse Stock Split - [at noodls] - May 27, 2016 BERKELEY HEIGHTS, N.J., May 27, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ('Cyclacel' or the 'Company'), a biopharmaceutical company developing oral ...
05/27/16 04:06 PMCYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Material Modification to Rights of Security Holders, Amendments to -
05/27/16 11:41 AMHold Calls Count For Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) At 0 - RealistInvestor.com - Hold Calls Count For Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) At 0RealistInvestor.comBuy calls count on Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC)'s stock stands at 0 while Sell recommendations is 0. Hold recommendation is 0. Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) has a total of 1 Strong Buy recommendations and 0 Strong ...and more »
05/25/16 01:12 PMTrader's Watch List: Cyclacel Pharmaceuticals, (NASDAQ:CYCC), Concord Medical Services (NYSE:CCM), M/I Homes ... - KC Register - Trader's Watch List: Cyclacel Pharmaceuticals, (NASDAQ:CYCC), Concord Medical Services (NYSE:CCM), M/I Homes ...KC RegisterCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) announced the publication of an abstract selected for an oral presentation on Phase 1 data of an orally administered, combination regimen of seliciclib and sapacitabine in 67 patients with advanced solid ...What's in Cyclacel Pharmaceuticals Inc After Forming Multiple Bottom Pattern?Franklin Independentall 2 news articles »
05/21/16 12:59 PMRevenue Update on Cyclacel Pharmaceuticals Inc(NASDAQ:CYCC) - Trade Calls - Revenue Update on Cyclacel Pharmaceuticals Inc(NASDAQ:CYCC)Trade CallsCyclacel Pharmaceuticals Inc(NASDAQ:CYCC) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during After-hours on May 11, 2016. Earnings per share were $-0.09. Cyclacel Pharmaceuticals Inc (CYCC) made into the ...
05/20/16 01:24 PMCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) One-Year Price Projection At $5 - Investor Newswire - Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) One-Year Price Projection At $5Investor NewswireSell-side analysts are certain on the prospect of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) stock. As of 2016-05-19, the stock ABR stands at 1. This type of rating states that whenever a stock has a score of 5, investors should avoid investing in ...and more »
05/19/16 06:22 AMCyclacel's Seliciclib-Sapacitabine Abstract Selected for Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting - [at noodls] - May 19, 2016 BERKELEY HEIGHTS, N.J., May 19, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), today announced the publication of an abstract ...
05/19/16 06:00 AMCyclacel’s Seliciclib-Sapacitabine Abstract Selected for Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting - [GlobeNewswire] - BERKELEY HEIGHTS, N.J., May 19, 2016-- Cyclacel Pharmaceuticals, Inc., today announced the publication of an abstract selected for an oral presentation on Phase 1 data of an orally administered, combination ...
05/17/16 01:55 PMAfter Last Week What Do Analysts Think Of Cyclacel Pharmaceuticals, Inc. (CYCC) - Share Trading News - After Last Week What Do Analysts Think Of Cyclacel Pharmaceuticals, Inc. (CYCC)Share Trading NewsThey now have a USD 9 price target on the stock. The share price of Cyclacel Pharmaceuticals, Inc. (CYCC) was up +5.69% during the last trading session, with a day high of 0.37. 83376 shares were traded on Cyclacel Pharmaceuticals, Inc.'s last session.
05/15/16 07:18 AMCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) One-Year Mean Price Target At $5 - Investor Newswire - Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) One-Year Mean Price Target At $5Investor NewswireSell-side analysts are confident on the future outlook of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) stock. As of 2016-05-13, the stock has an ABR of 1 rating, where number 5 denotes a Strong Sell and 1 Strong Buy. The ABR is reached on the basis of ...and more »
05/13/16 03:15 PMCYCLACEL PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report -
05/12/16 07:52 AMCyclacel Pharma (CYCC) Reports Q1 Loss of $0.09 - StreetInsider.com - Cyclacel Pharma (CYCC) Reports Q1 Loss of $0.09StreetInsider.comCyclacel Pharma (NASDAQ: CYCC) reported Q1 EPS of ($0.09), versus ($0.19) reported last year. Revenue for the quarter came in at $139 million, versus $512 million reported last year. Based on current plans, the Company estimates that it has capital ...and more »
05/12/16 07:52 AMCyclacel Pharmaceuticals Inc (CYCC) Releases Quarterly Earnings Results - Washington News Wire - Washington News WireCyclacel Pharmaceuticals Inc (CYCC) Releases Quarterly Earnings ResultsWashington News WireCyclacel Pharmaceuticals Inc (NASDAQ:CYCC) announced its earnings results on Wednesday. The company reported ($0.09) earnings per share for the quarter, MarketBeat.Com reports. Separately, Zacks Investment Research downgraded shares of ...Cyclacel Pharmaceuticals Inc (CYCC) Announces Earnings ResultsWeb Breaking NewsCyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q1 2016 Results - Earnings Call TranscriptSeeking AlphaCyclacel Pharmaceuticals Reports First Quarter 2016 Financial ResultsGlobeNewswire (press release)Sonoran Weekly Reviewall 5 news articles »
05/11/16 04:07 PMCyclacel Pharmaceuticals Reports First Quarter 2016 Financial Results - [at noodls] - May 11, 2016 BERKELEY HEIGHTS, N.J., May 11, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ('Cyclacel' or the 'Company'), a biopharmaceutical company developing oral ...
05/11/16 06:07 AMQ1 2016 Cyclacel Pharmaceuticals Inc Earnings Release - After Market Close -
05/05/16 07:21 AMCyclacel Pharmaceuticals to Release First Quarter 2016 Financial Results - GlobeNewswire (press release) - Cyclacel Pharmaceuticals to Release First Quarter 2016 Financial ResultsGlobeNewswire (press release)BERKELEY HEIGHTS, N.J., May 04, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell ...and more »
05/04/16 06:00 AMCyclacel Pharmaceuticals to Release First Quarter 2016 Financial Results - [GlobeNewswire] - BERKELEY HEIGHTS, N.J., May 04, 2016-- Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer ...

Social

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc. develops therapies that harness the power of the immune system to treat cancer and other serious illnesses. The Company develops proprietary techniques of antibody engineering to develop antibody-based products for the applications in immunology, oncology, and infectious diseases. Xcyte Therapies is currently conducting Phase I/II clinical trials in hormone-refractory prostate cancer, multiple myeloma and chronic lymphocytic leukemia.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CYCC
  • CUSIP:
Key Metrics:
  • Previous Close: $4.87
  • 50 Day Moving Average: $5.20
  • 200 Day Moving Average: $4.79
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $14.64M
  • Beta: 3.59
Additional Links:
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Chart for Wednesday, July, 27, 2016